What is the normal tissues morbidity following Helical Intensity Modulated Radiation Treatment for cervical cancer?. Issue 3 (June 2015)

• Record Type: Journal Article
• Authors: Mouttet-Audouard, Raphaelle; Lacornerie, Thomas; Tresch, Emmanuelle; Kramar, Andrew; Le Tinier, Florence; Reynaert, Nick; Leblanc, Eric; Narducci, Fabrice; Lartigau, Eric; Nickers, Philippe
• Is Part Of: Radiotherapy and oncology. Volume 115:Issue 3(2015:Jun.)
• Page Start: 386
• Page End: 391
• Publication Date: 2015-06
• Subjects: Oncology -- Periodicals; Radiotherapy -- Periodicals; Tumors -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- radiotherapy -- Periodicals; Radiotherapy -- Periodicals; Radiothérapie -- Périodiques; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Electronic journals; 616.9940642
• DOI: 10.1016/j.radonc.2015.02.010
• Languages: English
• ISSNs: 0167-8140

Abstract

<abstract xml:lang="en" abstract-type="author" id="ab005"> <title id="st065">Abstract</title> <sec> <title id="st035">Background and purpose</title> <p id="sp0005">To report on normal tissues morbidity following IMRT for cervix cancer.</p> </sec> <sec> <title id="st040">Material and methods</title> <p id="sp0010">The first 61 patients of a prospective series were included. 50 Gy to the PTV 1(pelvis) and 60 Gy to the PTV 2 (centro-pelvic disease and GTV nodes) were delivered concomitantly in 28 fractions, followed by a brachytherapy boost. For the small bowel, 50 Gy was the maximal dose, while V45 and V40 had to be <50 cc and 200 cc, respectively. For the bladder, rectum and sigmoid structures, 60 Gy was the maximal dose, and V45 and V40 had to be <20% and <50%. Acute and late toxicity data were prospectively collected.</p> </sec> <sec> <title id="st045">Results</title> <p id="sp0015">The median follow-up period was 40 months (range: 23–60). 30% and 90% of acute and moderate late side effects were reported respectively. Considering the AUC data of the organs at risk (OAR) DVH, late morbidity and doses were significantly linked (<italic>p</italic> ⩽ 0.03), predominantly between 10 Gy and 40 Gy, considering the small bowel and sigmoid colon. The high dose regions exhibited no significant impact.</p> </sec> <sec> <title id="st050">Conclusion</title> <p id="sp0020">The moderate dose volumes represent the predominant cause of morbidity after IMRT. Prospective trials are thus required to investigate new ways of dose distribution within the OAR.</p> </sec> </abstract>